ADAGiO: Adoptive Zelltherapie zur Behandlung rezidivierender erwachsener Patienten mit OliGodendrogliOma (OG). (ADAGiO)

Inclusion Criteria:

• Male or female, aged 18 years and above

• Tumor tissue obtained on a screening consent is available.

• Confirmed with recurrent/progressive IDH-mutant 1p/19q co-deleted Oligodendroglioma WHO grade 2 or WHO grade 3 (Patients who received prior radiation must be more than 12 weeks from completion of radiation).

• Karnofsky Performance Status ≥ 60

• Must be a candidate for surgery/biopsy

• Adequate bone marrow and organ function as defined below:

  • ANC ≥ 1,000/mcL
  • Platelets ≥ 100,000/mcL
  • Hemoglobin ≥ 9 g/dL (can be transfused)
  • Serum creatinine ≤ 1.5 x IULN OR Creatinine clearance by Cockcroft-Gault ≥ 60 mL/min for patients with serum creatinine > 1.5 x IULN
  • Serum total bilirubin ≤ 1.5 x IULN OR Direct bilirubin ≤ IULN for patients with total bilirubin > 1.5 x IULN
  • AST (SGOT) and ALT (SGPT) ≤ 3 x IULN

• For females of childbearing potential, negative serum pregnancy test at enrollment

• For women and men of childbearing potential (WOCBP) must be willing to use acceptable contraceptive methods

Exclusion Criteria:

• Prior invasive malignancy (except for non-melanomatous skin cancer) unless disease free for ≥ 3 years.

• Metastases detected below the tentorium or beyond the cranial vault and leptomeningeal involvement.

• Multifocal disease, defined as more than one enhancing lesion separated by noncontiguous T2/FLAIR signal abnormality, as determined by the PI. This exclusion does not apply to patients presenting with a new, separate lesion outside the original tumor site at recurrence, provided the original site of disease remains stable, as determined by the PI.

• Corticosteroids equivalent to ≥ 4mg dexamethasone daily.

• HIV, Hepatitis B, or Hepatitis C seropositive.

• Known active infection or immunosuppressive disease.

• Autoimmune disease requiring medical management with immunosuppressant.

• Pregnancy or lactation, due to possible adverse effects on the developing fetus or infant.

• Treatment with another investigational drug or other intervention within 30 days prior to projected first dose of study treatment (Priming phase with TTRNA-DC).

• Severe, active co-morbidity, defined as follows:

  • Unstable angina and/or congestive heart failure requiring hospitalization.
  • Transmural myocardial infarction within the last 6 months.
  • Acute bacterial or fungal infection requiring intravenous antibiotics at time of enrollment.
  • Chronic Obstructive Pulmonary Disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy.
  • Hepatic insufficiency resulting in clinical jaundice and/or coagulation defects.
  • Acquired Immune Deficiency Syndrome (AIDS) based upon current CDC definition. The need to exclude patients with AIDS from this protocol is necessary because the treatments involved in this protocol may be significantly immunosuppressive.
  • Major medical illnesses or psychiatric impairments that, in the investigator's opinion, will prevent administration or completion of protocol therapy.